Skip to Main Content

Paper Details

Routine versus As-Needed Bevacizumab with 12-Weekly Assessment Intervals for Neovascular Age-Related Macular Degeneration: 92-Week Results of the GMAN Trial.
Ophthalmology
9
2015
Author NameAffiliation
Sajjad MahmoodManchester Royal Eye Hospital, Central Manchester University Hospitals NHS Foundation Trust, Institute of Human Development, University of Manchester
  • 1 - 1

Datasets

Release 1.2